PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojLNE05KM7:TR?= M4PoT|I1NzR6L{eyJIg> M2KzWIlv\HWlZYOgeIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXSrb36gc44hVkJiY3XscEBoem:5dHi= MYiyOlIzPDZ6MR?=
SH-SY5Y M17TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[5V3VUOC16IN88US=> NGLSN28zPC92OD:3NkBp M4X4Volv\HWlZYOgeIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXSrb36gc44hVkJiY3XscEBoem:5dHi= MofENlYzOjR4OEG=
SH-SY5Y  NHLtWlZCeG:ydH;zbZMhSXO|YYm= NH3Z[pUyKM7:TR?= NVHB[Y9QOC53LUK0JIg> MX3z[Y5{cXSrenXzJI5mfXKxYnzhd5RwdWFiY3XscJMhfG9iZH;4c5J2[mmlaX6tbY5lfWOnZDDhdI9xfG:|aYO= M4DzTVI3OjJ2Nkix
G 35 SC NWfXRYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BWGIxNjB3LUKwJO69VQ>? M3fTflI1Nzd{IHi= NWHMdmx4TE2VTx?= MonCbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NF71WGgzPjF{MUK1NS=>
G 38 SC NITmOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PEc|AvODVvMkCg{txO M1XSWlI1Nzd{IHi= MXfEUXNQ M1HS[4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NEHRfXIzPjF{MUK1NS=>
G 40 SC M4fCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvUXGYzOC5yNT2yNEDPxE1? NWjX[4JnOjRxN{KgbC=> M1uxT2ROW09? MYrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NGe0e5QzPjF{MUK1NS=>
G 35 DC M{Lncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXewMlA2NTJyIN88US=> Mkj3NlQwPzJiaB?= M2fuWWROW09? MkDYbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? M{W3TFI3OTJzMkWx
G 38 DC NVjQN5ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlztNE4xPS1{MDFOwG0> M{fwdFI1Nzd{IHi= MnTiSG1UVw>? M3PNVolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NIHtT2wzPjF{MUK1NS=>
G 40 DC MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSwMlA2NTJyIN88US=> MoLuNlQwPzJiaB?= MW\EUXNQ M4jEd4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MWeyOlEzOTJ3MR?=
RD MVfBdI9xfG:|aYOgRZN{[Xl? NE\WXWQyNzFwNT:yJO69VQ>? NUHQTJRjPzJiaB?= NX;K[2pxcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? NFnrXFkzPTd2OUO3PC=>
TE381.T M2WwSWFxd3C2b4Ppd{BCe3OjeR?= MWWxM|EvPS9{IN88US=> NUWyTpNPPzJiaB?= M4jaZ4lv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy NUPQW5liOjV5NEmzO|g>
RMS13 NEXYPZFCeG:ydH;zbZMhSXO|YYm= MUGxM|EvPS9{IN88US=> NIjMeJo4OiCq M{HTO4lv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy NVvmb3pTOjV5NEmzO|g>
RH30  NET4N3NCeG:ydH;zbZMhSXO|YYm= NEjONHkyNzFwNT:yJO69VQ>? M1;FXlczKGh? NUDQNGYzcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? NVLrPGV[OjV5NEmzO|g>
VJ MoTyRZBweHSxc3nzJGF{e2G7 MmTvNU8yNjVxMjFOwG0> Ml63O|IhcA>? NH;mUHJqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? NYTtUY01OjV5NEmzO|g>
HS578T MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFXBOWExNTNizszN NVTlVFlwPzJiaB?= M37NZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M1HqWlI2PzJzNEG5
BT549 Mk\pR4VtdCCYaXHibYxqfHliQYPzZZk> M3SxOVAuOyEQvF2= MlvIO|IhcA>? M1;jbIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MXWyOVczOTRzOR?=
MDA-MB-231 NF;SVI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHnPelUxNTNizszN NYrKOFVJPzJiaB?= NXq0ZYZ{cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MXGyOVczOTRzOR?=
MDA-MB-468 NV35SXY3S2WubDDWbYFjcWyrdImgRZN{[Xl? MlLkNE0{KM7:TR?= MUS3NkBp M1;ZSYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M3XZUlI2PzJzNEG5
MDA-MB-436 NIO1RWRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NG\TXYYxNTNizszN NHjLT2U4OiCq NWDMeYJ1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NVfh[o1jOjV5MkG0NVk>
SUM149PT NUn2bnRGS2WubDDWbYFjcWyrdImgRZN{[Xl? MWOwMVMh|ryP MlftO|IhcA>? M2D5SIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? Mk\YNlU4OjF2MUm=
MDA-MB-468 NXHGenNmTnWwY4Tpc44hSXO|YYm= NVO2R|JDOC5yMT2xNEDPxE1? NVS4OHNmOjRiaB?= NFTNcHRld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NIXXdG8zPTd{MUSxPS=>
MDA-MB-231 NITXZpZHfW6ldHnvckBCe3OjeR?= MUmwMlAyNTFyIN88US=> MVqyOEBp NHvzboxld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NInFTY8zPTd{MUSxPS=>
HS578T NWfmfIhWTnWwY4Tpc44hSXO|YYm= NFnhc2YxNjBzLUGwJO69VQ>? NHvxUW4zPCCq MmXL[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? MXeyOVczOTRzOR?=
SW872 MkKxSpVv[3Srb36gRZN{[Xl? NXfpUVFlOC5yMT2wMlUh|ryP NX;XSWNVOjRiaB?= NWDye|A{emWmdXPld{BCU1RicHjvd5Bpd3K7bHH0bY9vKCiyQVvULUBidmRiNFXCVFEheGixc4Doc5J6dGG2aX;uJEhxPEWEUEGpJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MYGyOFY6PTZ|Mh?=
SW982 NHfXc4NHfW6ldHnvckBCe3OjeR?= MWOwMlAyNTBwNTFOwG0> M1;2VlI1KGh? M2PtSpJm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NGC5VmQzPDZ7NU[zNi=>
SW872 M{GxfmFxd3C2b4Ppd{BCe3OjeR?= NYXuVVBpOC5yMT2wMlUh|ryP MWq0PEBp NHjpe|RqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MmjsNlQ3QTV4M{K=
SW982 NEDNT5JCeG:ydH;zbZMhSXO|YYm= M{D2[FAvODFvMD61JO69VQ>? M3TmXFQ5KGh? M2W1XYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= M37uV|I1Pjl3NkOy
AGS HG NVH5[ZpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwNkigxtEhOC5yM{Gg{txO M4LkclI1PTl5NEe4
AGS LG MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Hxe2lEPTB;MD6wOUDDuSByLkCwNUDPxE1? NYnrWoVGOjR3OUe0O|g>
HGC27 HG NFXmT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXBVI1KSzVyPUCuN|ghyrFiMD6wNlIh|ryP M4KxdFI1PTl5NEe4
HGC27 LG M1HuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DWXmlEPTB;MD6wNkDDuSByLkCwOEDPxE1? MYWyOFU6PzR5OB?=
MKN45 HG MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITXb|FKSzVyPUGuNFEhyrFiMD6wOVEh|ryP MVeyOFU6PzR5OB?=
MKN45 LG NUnRO5ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD1fVZ{UUN3ME2wMlg4KMLzIECuNFMxKM7:TR?= NXTEfVJlOjR3OUe0O|g>
NUGC4 HG M3PZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT6W2FrUUN3ME2xOE4xKMLzIEOuPVE{KM7:TR?= NYnyW2VCOjR3OUe0O|g>
NUGC4 LG NIrySW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWyd5k4UUN3ME2xOE4xKMLzIEWuN|IyKM7:TR?= MkXZNlQ2QTd2N{i=
A549 M17TdGZ2dmO2aX;uJGF{e2G7 MXewMlI2NzBwNT:xJO69VQ>? Mnq4NlQhcA>? M2XNc4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2yrZ3j0cJk> NWewZoVyOjR|NUG0NlU>
H460 NHjoWYdHfW6ldHnvckBCe3OjeR?= NXPPN|Z4OC5{NT:wMlUwOSEQvF2= NHqzbGkzPCCq Mkj2bY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=> MX[yOFM2OTR{NR?=
H661 MVnGeY5kfGmxbjDBd5NigQ>? NVrpOolJOC5{NT:wMlUwOSEQvF2= NGDze2kzPCCq M1zON4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= M2\HdVI1OzVzNEK1
SAS MoHWSpVv[3Srb36gRZN{[Xl? M2X1SFAvOjVxMD61M|Eh|ryP NFnYV|czPCCq M4jBWIlvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= M1;Ne|I1OzVzNEK1
UT5 M{n3[2Z2dmO2aX;uJGF{e2G7 M3XIe|AvOjVxMD61M|Eh|ryP NYjweZdDOjRiaB?= M4HGeIlvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= NVy2[WY4OjR|NUG0NlU>
FaDu Mly1SpVv[3Srb36gRZN{[Xl? MkT2NE4zPS9yLkWvNUDPxE1? M373OlI1KGh? MYnpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NXfrO2xIOjR|NUG0NlU>
RD MWnBdI9xfG:|aYOgRZN{[Xl? NWnIc3VHOS9zLkWvNkDPxE1? MUW3NkBp M2DISWROW09? MYrpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 NFnOVlEzOzZ6NEmyOS=>
TE671 NETnV4VCeG:ydH;zbZMhSXO|YYm= NV7NZmZqOS9zLkWvNkDPxE1? M2LxeFczKGh? MnziSG1UVw>? NWP6O3lvcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? MXWyN|Y5PDl{NR?=
RH30  M4PWfmFxd3C2b4Ppd{BCe3OjeR?= NUL1dGk1OS9zLkWvNkDPxE1? MonOO|IhcA>? M{\F[WROW09? NGjZUYtqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NE[4VYEzOzZ6NEmyOS=>
RMS13 MVHBdI9xfG:|aYOgRZN{[Xl? M2LI[FEwOS53L{Kg{txO NYPQ[XJmPzJiaB?= NEfnfnJFVVOR MlfabY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> MUiyN|Y5PDl{NR?=
SUM149PT MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2TXbVAvOyEQvF2= MXS3NkBp M4nGOYVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? NIixSnczOzZyMUC3OC=>
MDA-MB-468 NHTvbnlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYiwMlMh|ryP M{\wW|czKGh? M2PRTIVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? M4TpUlI{PjBzMEe0
MDA-MB-231 Mn7qR4VtdCCYaXHibYxqfHliQYPzZZk> M4jBe|AvOyEQvF2= NWWxUVRjPzJiaB?= M3Tm[YVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? NHjx[5gzOzZyMUC3OC=>
SY5Y NWP5V4Z5TnWwY4Tpc44hSXO|YYm= MYWxMlUwOi53L{Wg{txO NYnJOGxHOjRiaB?= MWfpcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| MkfRNlM{Pzh|NEG=
SKNBE(2c) M13zWGZ2dmO2aX;uJGF{e2G7 MlWxNU42NzJwNT:1JO69VQ>? M1jK[|I1KGh? M4jJVolv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= NVW3eIR5OjN|N{izOFE>
RD M4TnVmFxd3C2b4Ppd{BCe3OjeR?= MVqzJOK2VQ>? NYLDbng1OTJiaB?= NXTIPIpNTE2VTx?= NFvxcmx{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> M2jRcFI{OzByOEC5
TP5014 NWfZdWFZSXCxcITvd4l{KEG|c3H5 M3jBVFMhyrWP NH;qXXcyOiCq NUnLfVlzTE2VTx?= M2fyepNmdnOrdHn6[ZMhWkRiY3XscJMhfG9iRF;YMYlv\HWlZXSgZZBweHSxc3nz Mk\vNlM{ODB6MEm=
HT1080 NUTqd4RMSXCxcITvd4l{KEG|c3H5 NFL4VZA{KML3TR?= NYnHRZVlOTJiaB?= NHXENWpFVVOR MUHz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= M13YclI{OzByOEC5
A549 NGDoNGRHfW6ldHnvckBCe3OjeR?= Mo\iNE0{NjNizszN MlfPO|IhcA>? M335folv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? Mm[zNlMzPTl3OUG=
HCC827 NVvv[YpCTnWwY4Tpc44hSXO|YYm= MlfaNE0{NjNizszN MonHO|IhcA>? MXPpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> MojTNlMzPTl3OUG=
H3122 NEm3bHFHfW6ldHnvckBCe3OjeR?= NVjVdpJTOC1|LkOg{txO MYW3NkBp MXTpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> MmP1NlMzPTl3OUG=
TALL-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml33NgKBkc7:TR?= M4nKOFch\A>? M2[2TIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M1S3RVI{ODN6Mkez
HPB-ALL M4f6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PzS|HjiIoQvF2= MnrlO{Bl MWTk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MlX0NlMxOzh{N{O=
DND41 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULUOYNLOeLCid88US=> MoPJO{Bl M1:5[oRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M4XQTVI{ODN6Mkez
SUP-T1 NY[1dXdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUex5qCK|ryP NXzROWNXPyCm NWjlTY9z\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MnTqNlMxOzh{N{O=
PEER MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDQW3NCOeLCid88US=> MUm3JIQ> NV:zcJUz\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MXyyN|A{QDJ5Mx?=
ALL-SIL M13sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G2UlHjiIoQvF2= MYO3JIQ> NVnVT4Js\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NIfBTGYzOzB|OEK3Ny=>
KE37 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[x5qCK|ryP NGnQOpM4KGR? NHi2Vldl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NFfWSoYzOzB|OEK3Ny=>
Karpas-45 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWix5qCK|ryP MYK3JIQ> NIXTcHBl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MUeyN|A{QDJ5Mx?=
RPMI-8402 NGTJd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrBNJYy6oDLzszN NH;rS4M4KGR? NF;vZ3Rl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MYiyN|A{QDJ5Mx?=
Jurkat NGfGR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzoZlYy6oDLzszN NEflbmk4KGR? MYrk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NEXYT4wzOzB|OEK3Ny=>
MOLT-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDzVHRFOeLCid88US=> NFf6RYg4KGR? NGLab5Vl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MojXNlMxOzh{N{O=
PF-382 NEPZUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO2NgKBkc7:TR?= M2G4WVch\A>? NXvqN|Ay\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M3zaUlI{ODN6Mkez
CCRF-CEM MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDPNgKBkc7:TR?= MUe3JIQ> MUXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NVvXOIpSOjNyM{iyO|M>
LOUCY MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PpN|HjiIoQvF2= M4D6XVch\A>? M4q3ToRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? Ml7JNlMxOzh{N{O=
MOLT-16 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHSRZEy6oDLzszN MX63JIQ> NGjFR|Rl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? M3jmfFI{ODN6Mkez
MM1S MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPyNYYxNTJizszN MVyyOEBp Ml\rTWM2OD1yLkWg{txO MVuyNlgzQTJ|NB?=
NCI-H929 NFX5cGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH4NE0zKM7:TR?= NEDxTo8zPCCq MVzJR|UxRTBwMkWg{txO MVyyNlgzQTJ|NB?=
KMS12-BM  NWXvbZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\TUGMxNTJizszN NEeyTWYzPCCq MXjJR|Ux97zgMjFOwG0> NXH0SJJ5OjJ6MkmyN|Q>
MDA-MB-436 MWjGeY5kfGmxbjDBd5NigQ>? M4\ZZlEh|ryP MWOyOEBp MoLYdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MlrONlI1QDh3OUC=
SUM149PT M{H6TmZ2dmO2aX;uJGF{e2G7 M3vKSVEh|ryP MmTGNlQhcA>? MVHy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NIPQZXUzOjR6OEW5NC=>
SUM1315MO2 MWLGeY5kfGmxbjDBd5NigQ>? M2XPfVEh|ryP NEfUTXYzPCCq NEH5VI5z\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NFLHSJgzOjR6OEW5NC=>
HCC1937 M3iyTGZ2dmO2aX;uJGF{e2G7 NEnNZnoyKM7:TR?= Mk\aNlQhcA>? M3zGepJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= NUXCZWZtOjJ2OEi1PVA>
HCC827 NInFWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSwMVMh|ryP M2CyVVczKGh? NGfHOnlKSzVyPUCuN{DPxE1? MViyNVIzODR5NB?=
PC-9  NYPY[ndpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojkNE0{KM7:TR?= NIDMcYM4OiCq MVTJR|UxRTBwODFOwG0> M{TiW|IyOjJyNEe0
LN229 MUnGeY5kfGmxbjDBd5NigQ>? M4nne|Eh|ryP NUC4NmxNPDhiaB?= M3HXeYlv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? MoW3NlExPjJ7OUO=
U87 MmP0SpVv[3Srb36gRZN{[Xl? NWrKU281OSEQvF2= MYG0PEBp M3Gx[olv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? NFLLZYUzOTB4Mkm5Ny=>
U373 NHXWbGhHfW6ldHnvckBCe3OjeR?= MmrRNUDPxE1? NEXn[mQ1QCCq M3PsNYlv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? MXOyNVA3Ojl7Mx?=
SF767 M1rKcmZ2dmO2aX;uJGF{e2G7 M{Li[lEh|ryP NFn3OII1QCCq MkflbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? NX\MVY9qOjFyNkK5PVM>
Mel-Juso NViye4hSS2WubDDWbYFjcWyrdImgRZN{[Xl? MkK3NE4xOeLCk{Gw5qCK|ryP MnTiO|IhcA>? NV60WYJMcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MlvXNlExPDh5OEW=
518A2  NHLEW5ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYfFXZN5OC5yMfMAl|Ex6oDLzszN M2nUTVczKGh? MU\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NIfPW2UzOTB2OEe4OS=>
Mel-Juso  MUjGeY5kfGmxbjDBd5NigQ>? MYewMlAxOeLCk{JihKnPxE1? MofINlQhcA>? M{PU[JN2eHC{ZYPz[ZMheGixc4Doc5J6dGG2aX;uJI9nKHCqb4PwbIF1cWS7bDDpco9{cXSxbDCzMYtqdmG|ZTDkc5dve3S{ZXHtJJRiemendIO= NX;5OYx4OjFyNEi3PFU>
518A2 NGrXRpRHfW6ldHnvckBCe3OjeR?= NVHGOVNZOC5yMEJihLMy6oDLzszN NXLmSnhUOjRiaB?= NGWxO2N{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz MW[yNVA1QDd6NR?=
PC3  NXnCWpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSyOIg> MV3HTVUxyqB;IEGwNEBvVQ>? NUXXd3FmOjB3NUGwOlE>
U87MG NH;4e2xHfW6ldHnvckBCe3OjeR?= M1rmblAvOS1zIN88US=> MYmyOQKBkWkEoB?= NEXj[4lFVVOR NHLCTY5qdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= M2n6O|E6PjN|Nkiz
U138MG MY\GeY5kfGmxbjDBd5NigQ>? M2LoSFAvOS1zIN88US=> MV2yOQKBkWkEoB?= M3jDVmROW09? M2HRXIlvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p Ml[4NVk3OzN4OEO=
U118MG NIT3eWRHfW6ldHnvckBCe3OjeR?= MlHWNE4yNTFizszN MYGyOQKBkWkEoB?= NF74eJFFVVOR MX7pcohq[mm2czDQTVNMNW2nZHnheIVlKHOrZ37hcIlv\w>? MX:xPVY{OzZ6Mx?=
U87MG MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3lXnd4UUN3ME2wMlE1KM7:TR?= NF34WYEyQTV6NEKyOy=>
IGROV-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\EWGlEPTB;MD6wOkDPxE1? MkfpNVk2QDR{Mke=
DETROIT562 NXjJUZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnuPJFKSzVyPUCuNVMh|ryP MnfjNVk2QDR{Mke=
PC3  NYTBcYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjXTWM2OD1yLkGwJO69VQ>? NFz0PFgyQTV6NEKyOy=>
SKOV-3 M3LaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnzRWtKSzVyPUCuNVIh|ryP NXi0PIJWOTl3OESyNlc>
HUVEC Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEig{txO MXKxPVU5PDJ{Nx?=
UCH-1  NXrZSohNTnWwY4Tpc44hSXO|YYm= MonXNE02KM7:TR?= NUHUS41[cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDic5RpKEGNVDDhcoQhdVSRUjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGrRbGkyQTV{OES0NS=>
UCH-1  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMlAyNTFyIN88US=> MnXZOkBl NEKyfG9qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHTvd4Uh\GWyZX7k[Y51dHl? MkDTNVk2Ojh2NEG=
UCH-1  MmDVRZBweHSxc3nzJGF{e2G7 MUiwMlEuOTBizszN MV6yOEBp M2[1U2ROW09? MlPLbY5lfWOnczDhdI9xfG:|aYO= NXm1Nms5OTl3Mki0OFE>

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

カスタマーフィードバック (4)


Click to enlarge
Rating
Source Mol Carcinog, 2012, 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog, 2012, ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine, PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ